C4 Therapeutics Inc (NASDAQ: CCCC) on Monday, soared 3.52%% from the previous trading day, before settling in for the closing price of $1.42. Within the past 52 weeks, CCCC’s price has moved between $1.09 and $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -8.92% annually for the last half of the decade. The company achieved an average annual earnings per share of -12.41%. With a float of $54.24 million, this company’s outstanding shares have now reached $70.99 million.
In an organization with 110 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.25%, operating margin of -292.99%, and the pretax margin is -259.27%.
C4 Therapeutics Inc (CCCC) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of C4 Therapeutics Inc is 23.61%, while institutional ownership is 80.35%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -12.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.31% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
C4 Therapeutics Inc (CCCC) is currently performing well based on its current performance indicators. A quick ratio of 5.70 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.96 million. That was inferior than the volume of 1.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.93%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 13.82%, which indicates a significant decrease from 34.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.56% in the past 14 days, which was higher than the 94.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4646, while its 200-day Moving Average is $3.4837. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $1.5067. Second resistance stands at $1.5433. The third major resistance level sits at $1.6167. If the price goes on to break the first support level at $1.3967, it is likely to go to the next support level at $1.3233. Assuming the price breaks the second support level, the third support level stands at $1.2867.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
Market capitalization of the company is 104.38 million based on 71,007K outstanding shares. Right now, sales total 35,580 K and income totals -105,320 K. The company made 7,240 K in profit during its latest quarter, and -26,320 K in sales during its previous quarter.
